W4P-RBD
An experimental COVID-19 DNA-based vaccine.
General information
W4P-RBD is an experimental DNA-based COVID-19 vaccine. It was engineered by fusing the SARS-CoV-2 sequence encoding RBD with a 33-base pair sequence from hepatitis B virus (HBV) preS1 region carrying W4P mutation. The vaccine (a 3-dose regimen) induced robust neutralizing IgG and IgA responses and T cell responses in vaccinated mice, with the HBV sequence displaying an adjuvant potential (Jeong et al., 2021).
Supporting references
| Link | Tested on | Impact factor | Notes | Publication date |
|---|---|---|---|---|
|
A Novel DNA Vaccine Against SARS-CoV-2 Encoding a Chimeric Protein of Its Receptor-Binding Domain (RBD) Fused to the Amino-Terminal Region of Hepatitis B Virus preS1 With a W4P Mutation
Spike protein DNA Animal model In vitro |
Huh-7, Calu-3, and Vero E6 cells (neutralization asssays); C57BL/6 mice; SARS-CoV-2 Spike pseudotyped virus and live virus | 5.09 | The vaccine induced robust neutralizing IgG and IgA responses and IFNγ- and TNFα-releasing CD4+ and CD8+ T cell responses in vaccinated mice, with the HBV sequence displaying an adjuvant potential (recognized based on IL-6 and TNFα production). |
Feb/26/2021 |
